Ember Therapeutics Stock Fundamentals
| EMBT Stock | USD 0.0001 0.00 0.00% |
Ember Therapeutics fundamentals help investors to digest information that contributes to Ember Therapeutics' financial success or failures. It also enables traders to predict the movement of Ember Pink Sheet. The fundamental analysis module provides a way to measure Ember Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ember Therapeutics pink sheet.
Ember |
Ember Therapeutics Company Price To Earning Analysis
Ember Therapeutics' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Current Ember Therapeutics Price To Earning | 26.61 X |
Most of Ember Therapeutics' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ember Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
| Competition |
Based on the latest financial disclosure, Ember Therapeutics has a Price To Earning of 26.609 times. This is 2.98% higher than that of the sector and notably higher than that of the Price To Earning industry. The price to earning for all United States stocks is 7.35% higher than that of the company.
Ember Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ember Therapeutics's current stock value. Our valuation model uses many indicators to compare Ember Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ember Therapeutics competition to find correlations between indicators driving Ember Therapeutics's intrinsic value. More Info.Ember Therapeutics is rated below average in current valuation category among its peers. It also is rated below average in shares outstanding category among its peers creating about 3.33 of Shares Outstanding per Current Valuation. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ember Therapeutics' earnings, one of the primary drivers of an investment's value.Ember Price To Earning Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ember Therapeutics' direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Ember Therapeutics could also be used in its relative valuation, which is a method of valuing Ember Therapeutics by comparing valuation metrics of similar companies.Ember Therapeutics is currently under evaluation in price to earning category among its peers.
Ember Fundamentals
| Current Valuation | 12 M | |||
| Shares Outstanding | 40 M | |||
| Shares Owned By Insiders | 65.00 % | |||
| Price To Earning | 26.61 X | |||
| EBITDA | 9.4 M | |||
| Net Income | (23.24 K) | |||
| Cash And Equivalents | 71.22 M | |||
| Cash Per Share | 0.41 X | |||
| Total Debt | 75 K | |||
| Debt To Equity | 0.33 % | |||
| Current Ratio | 3.32 X | |||
| Book Value Per Share | (0.74) X | |||
| Cash Flow From Operations | (16.72 K) | |||
| Beta | 3.33 | |||
| Market Capitalization | 926.88 K | |||
| Total Asset | 184 | |||
| Retained Earnings | 289 K | |||
| Working Capital | 58.61 M | |||
| Current Asset | 83.91 M | |||
| Current Liabilities | 25.3 M | |||
| Net Asset | 184 |
About Ember Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ember Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ember Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ember Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York. Ember Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Ember Pink Sheet Analysis
When running Ember Therapeutics' price analysis, check to measure Ember Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ember Therapeutics is operating at the current time. Most of Ember Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ember Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ember Therapeutics' price. Additionally, you may evaluate how the addition of Ember Therapeutics to your portfolios can decrease your overall portfolio volatility.